No Data
No Data
Compugen Announces USPTO Grants New Patent for Use of COM902
Express News | Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use of Com902 (Reduced Fc Anti-Tigit) With Anti-Pd-1 and Anti-Pvrig Antibodies
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Truist Financial Maintains Compugen(CGEN.US) With Buy Rating
Compugen Reports Strong Q3 2024 Results and Progress